CDISC, Cohen Veterans Bioscience partner to create new therapeutic standard for PTSD

In an effort to establish uniform clinical research and terminology standards, the Clinical Data Interchange Standards Consortium and Cohen Veterans Bioscience recently partnered to develop a new CDISC Therapeutic Area Data Standard for PTSD.

“Establishing a suite of standards to support clinical research from protocol and data collection through analysis and reporting is an important tool that will accelerate the development of new and effective diagnostics and treatments for our service men and women and veterans that are affected by PTSD,” Magali Haas, MD, PhD, CEO and president of Cohen Veterans Bioscience, said in a press release. “Empowering data collection and sharing makes the most of the valuable information offered by patients participating in research studies around the globe and saves time and resources to unlock cures sooner.”

Bron Kisler

CDISC and Cohen Veterans Bioscience will analyze data from the NIH, U.S. Department of Defense and Veterans Affairs for PTSD medical research and clinical care to determine the most commonly used data elements and biomedical concepts in PTSD.

“Building upon our work in TBI, we are pleased to be launching another project that can lead to a greater understanding of mental health and better care for those suffering from PTSD. Developing a data standard for PTSD is an important step for CDISC, and for the many patients and families that experience this condition, and we appreciate Cohen Veterans Bioscience's offer to fund the project,” Bron Kisler, vice president of strategic alliances & development for CDISC, said in a press release. “The PTSD project is timely, as CDISC is also working on standards for PTSD and TBI comorbidity — major depressive disorder, general anxiety disorder, and bipolar disorder — funded by FDA as well as donations from the Association of the US Army North Texas & the Golden Rule Family Foundation.”